Cancer Diagnostics and Treatments (CDT) SBIR/STTR SEP – CDPT (13)
This Special Emphasis Panel reviews grant applications related to diagnosis and treatment of cancer. This includes identification of biomarkers as prognosticators of cancer, assay development for cancer diagnosis and prognosis, novel approaches to treating cancers with a focus on immunotherapies.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
Review Dates
Topics
- Discovery and validation of biomarkers for cancer detection, diagnosis, prognosis, and therapeutic responses
- Development of novel assays, use of instrumentation and algorithms for cancer screening, diagnosis, prediction of metastasis, recurrence, and drug responses
- Basic, pre-clinical and clinical testing for tumor genetic and epigenetic markers
- Pre-clinical and clinical modeling of carcinogenesis, tumor development, metastasis, prevention and treatment
- Development and evaluation of cancer immunotherapeutic agents and strategies (including cancer vaccines, therapeutic antibodies, adoptive T cells) in preclinical models, and translational studies leading to pilot and/or phase-1 clinical trials
Shared Interests and Overlaps
There are shared interests with Cancer Biotherapeutics Development (CBD) [OTC (12)] study section in cancer immunotherapeutic agents: Applications focused on developing cancer immunotherapies (antibody, vaccine, immune cell) and strategies may be assigned to OTC (13). Applications focused on an antibody conjugate or other antibody/ligand directed therapeutic approach or strategy for cancer may be assigned to OTC (12).
There are shared interests with Cancer Drug Development and Therapeutics (CDDT) [OTC (10)] study section in immune-modulating small molecule biologic agents or their derivatives for cancer: Applications focused on evaluating drugs primarily involved in modulating host-tumor immune interactions may be assigned to OTC (13). Applications focused on development or refinement of small molecule anti-cancer agents may be assigned to OTC (10).
There are shared interests with Small Business: Innovative Immunology [AIDC (10)] study section in immunoassays and immunologic markers development: Applications focused on clinical immunoassays or markers development for cancer early detection, risk stratification, or diagnosis/prognosis may be assigned to OTC (13). Applications focused on immunoassays and immunologic markers for transplantation, neoplastic diseases, and autoimmune diseases may be assigned to IMM (10).
There are shared interests with Small Business: Microbial Vaccine Development [AIDC (11)] study section in vaccine development: Applications focused on anti-cancer immunotherapeutic agents (antibody, cancer vaccine, immune cell) development may be assigned to OTC (13). Applications focused on the investigation of immune responses, therapeutics or novel vaccines against non-HIV infectious agents may be reviewed in IMM (12).
There are shared interests with Biological Chemistry, Biophysics, and Assay Development [IMST (10)] study section in technologies for biological measurements and biological assays. Applications focused on testing/evaluating developed or pilot technologies or assay methods for cancer early detection, risk stratification, or diagnosis/prognosis may be assigned to OTC (13). Applications focused on biochemistry, biophysics-based technologies or assay methods development may be assigned to IMST (10).
There are shared interests with Instrumentation, Environmental, and Occupational Safety [IMST (12)] study section in photonic, electronic instrumentation or devices. Applications focused on testing or evaluating developed or pilot photonic, optical, electronic instruments or devices for cancer early detection, risk stratification, or diagnosis/prognosis may be assigned to OTC (13). Applications focused on developing the photonic, electronic instruments or devices may be assigned to IMST (12).
There are shared interests with Computational, Modeling, and Biodata Management [IMST (14)] study section in computational algorithm, data modeling and biodata management. Applications focused on testing or evaluating developed or pilot algorithms, modeling or other bioinformatics methods for cancer early detection, risk stratification, or diagnosis/prognosis may be assigned to OTC (13). Applications focused on developing bioinformatics/computational methods, software and other technologies for biological data modeling, data mining, and data management may be assigned to IMST (14).
There are shared interests with Medical Imaging [SBIB (10)] study section in imaging device and imaging agents. Applications focused on testing or evaluating developed or pilot imaging device or imaging agent for cancer early detection, risk stratification, or diagnosis/prognosis may be assigned to OTC (13). Applications focused on development of imaging device/instrumentation or imaging agents may be assigned to SBIB (10).
There are shared interests with Biomedical Sensing, Measurement and Instrumentation [SBIB (11)] study section in biosensing device and instrumentation. Applications focused on testing or evaluating developed or pilot biosensing device or instrument for cancer early detection, risk stratification, or diagnosis/prognosis may be assigned to OTC (13). Applications focused on development of biosensing device or instrumentation may be assigned to SBIB (11).
